332 related articles for article (PubMed ID: 10857142)
1. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
2. [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Serment G; Rossi D; Reitz C; Boumendil O
Prog Urol; 2000 Apr; 10(2):254-60. PubMed ID: 10857143
[TBL] [Abstract][Full Text] [Related]
3. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Tsai YS; Lan SK; Ou JH; Tzai TS
Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
5. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
10. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Lukacs B; Leplège A; Thibault P; Jardin A
Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
Djavan B; Roehrborn CG; Shariat S; Ghawidel K; Marberger M
J Urol; 1999 Jan; 161(1):139-43. PubMed ID: 10037386
[TBL] [Abstract][Full Text] [Related]
14. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
[TBL] [Abstract][Full Text] [Related]
15. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
Low BY; Liong ML; Yuen KH; Chee C; Leong WS; Chong WL; Khan NA; Cheah PY; Liong KK
J Urol; 2008 Apr; 179(4):1461-9. PubMed ID: 18295277
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
17. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
Lukacs B; Grange JC; Comet D; Mc Carthy C
Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
Dogra PN; Biswas NR; Ravi AK; Mani K; Kumar V
J Indian Med Assoc; 2005 Feb; 103(2):108-10, 112. PubMed ID: 16008322
[TBL] [Abstract][Full Text] [Related]
19. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
Guthrie R
J Fam Pract; 1994 Aug; 39(2):129-33. PubMed ID: 7520053
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
